Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial.
By M. Hallek, K. Fischer, G. Fingerle-Rowson, A. Fink, R. Busch, J. Mayer, M. Hensel, G. Hopfinger, G. Hess, U. V. Grünhagen and 22 more. The Lancet, 2010
1,887 citations recorded by the source corpus.
Subfields: Building and Construction, Developmental and Educational Psychology, Software
View Paper: https://www.semanticscholar.org/paper/2b2aa2bccdf35fb429f28659a36d7ba6bb458d2d
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
- N. Wagner-Johnston
- R. Ulrich
- T. Robak
- C. Buske
- E. Montserrat
- P. Hillmen
- D. Benson
- C. Bello
Citations in the corpus
- Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. (2014, neutral): “Psychiatric 39 (16) 11 (9) 36 (15) 11 (9) 59 (18) 49 (15)”
- Mutations driving CLL and their evolution in progression and relapse (2015, neutral): “To overcome these challenges, we analyzed WES data from 538 CLLs, including 278 pre-treatment samples collected from subjects enrolled on the phase III CLL8 study 6 .”
- Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia (2014, neutral): “Allogeneic transplantation 3 (2) 1 (1)”
- Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia. (2014, background): “Across prospective Phase 3 trials and retrospective studies, the addition of rituximab appears to provide a survival advantage with initial therapy.(4,5) However, disease progression is inevitable, and resistant disease emerges, resulting in patients succumbing to their”
- Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia (2015, neutral): “Increased weight 16 (26) 15 (25) 1 (2)”
- Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2015, positive): “The formerly poor prognosis of patients with a del(11q) (∼20%) has been improved by chemoimmunotherapy with FCR (fludarabine, cyclophosphamide and rituximab) [9].”